Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 10Breast Neoplasms 9Prostatic Neoplasms 7Multiple Myeloma 6Colorectal Neoplasms 5Ovarian Neoplasms 4Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Head and Neck Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Recurrence 3Neoplasms, Plasma Cell 3Lung Neoplasms 3Hematologic Neoplasms 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Urinary Bladder Neoplasms 2Neoplasms by Site 2Mycoses 2Medication Adherence 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Leukemia 2Carcinoma, Transitional Cell 2COVID-19 2Adenocarcinoma 2Uveal Melanoma 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1

Interventions

valrubicin 3dodecyl maltoside 3Mitomycin 2Interferon beta-1b 2Gemcitabine 2pembrolizumab 1enfortumab vedotin 1cemiplimab 1apaziquone 1Standard of Care 1Oncolytic Virotherapy 1Interferons 1Imiquimod 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1BCG Vaccine 1ALT-801 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma in Situ × Standard of Care × Clear all
NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡